ReviewOpen forum infectious diseases2018
Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management.
Review in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05081271 (COVID-19 Booster Vaccination in Persons With Multiple Sclerosis), which is not on this map. Cited by 74 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
Who cites it
74 citing papers in PubMed, 3 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Pooled it
- MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis.Multiple sclerosis and related disorders · 2021Guideline
- COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review.Neurology(R) neuroimmunology & neuroinflammation · 2021Pooled it
- Evaluation of Documented Infections by Provider Specialty in Patients with Multiple Sclerosis Receiving Disease-Modifying Therapies: A Claims Database Analysis.Advances in therapy · 2026Article
- Manifestations of tuberculosis possibly associated with rituximab in a patient with diagnosed multiple sclerosis: a case report.Journal of medical case reports · 2026Article
- First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.Journal of neurology · 2025Article
- Gynecological health: A missing link in comprehensive treatment monitoring for multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Review
- Active tuberculosis and multiple sclerosis: the importance of screening before treatment.Arquivos de neuro-psiquiatria · 2025Article
- Review
- Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.Neurology · 2025Article
- Cytomegalovirus Infection in a Multiple Sclerosis Patient on Dimethyl Fumarate.Case reports in neurological medicine · 2025Article
- Infection and infestation-related adverse events of ocrelizumab: A disproportionality analysis using FDA adverse event reporting system.Northern clinics of Istanbul · 2025Article
- Shaping the role of plasma exchange in autoimmune neurology: lessons learned from 67 years and over 90,000 procedures.Therapeutic advances in neurological disorders · 2025Review
- Data-driven risk/benefit estimator for multiple sclerosis therapies.medRxiv : the preprint server for health sciences · 2024Article
- Seroprevalence of Toxoplasma gondii and Borrelia burgdorferi infections in patients with multiple sclerosis in Poland.Scientific reports · 2024Article
- [Treatment of psoriasis vulgaris : Therapy strategies for optimal patient-centered care].Dermatologie (Heidelberg, Germany) · 2024Review
- [Comorbidities in multiple sclerosis and their influence on the choice of treatment].Revista de neurologia · 2024Review
- Knowledge domain and trend of disease-modifying therapies for multiple sclerosis: A study based on CiteSpace.Heliyon · 2024Review
- CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based StudyNeurology · 2024Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedCorrigendum.2018
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis therapies include interferons, glatiramer, and multiple immunosuppressive drugs. Discerning infectious risks of immunosuppressive drugs requires understanding their mechanisms of action and analyzing interventional studies and postmarketing observational data. Though identical immunosuppressive therapies are sometimes used in non-neurologic conditions, infectious risks may differ in this population. Screening for and treatment of latent tuberculosis (TB) infection should be prioritized for patients receiving alemtuzumab; ocrelizumab is likely not associated with an increased risk of TB. Hepatitis B virus (HBV) reactivation can be devastating for patients treated with ocrelizumab and alemtuzumab, whereas the small molecule oral agents do not likely pose substantial risk of HBV. Progressive multifocal leukoencephalopathy is a particular concern with natalizumab. Alemtuzumab, and possibly natalizumab and fingolimod, risks herpes virus reactivation and may warrant prophylaxis. Unusual opportunistic infections have been described. Vaccination is an important tool in preventing infections, though vaccine timing and contraindications can be complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.